Market Cap
€2.9b
Last Updated
2020/06/01 21:40 UTC
Data Sources
Company Financials +
Executive Summary
Glanbia plc operates as a nutrition company.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet established dividend payer.
Similar Companies
Share Price & News
How has Glanbia's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GL9 has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
1.1%
GL9
1.6%
IE Food
2.1%
IE Market
1 Year Return
-34.7%
GL9
-0.3%
IE Food
0.7%
IE Market
Return vs Industry: GL9 underperformed the Irish Food industry which returned -0.3% over the past year.
Return vs Market: GL9 underperformed the Irish Market which returned -0% over the past year.
Shareholder returns
| GL9 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.1% | 1.6% | 2.1% |
| 30 Day | 1.8% | 1.7% | 7.9% |
| 90 Day | -14.2% | -3.4% | -5.3% |
| 1 Year | -33.0%-34.7% | 1.9%-0.3% | 1.9%0.7% |
| 3 Year | -42.3%-45.4% | 16.9%10.2% | 5.3%0.4% |
| 5 Year | -39.3%-43.4% | 47.3%33.8% | 36.5%26.3% |
Price Volatility Vs. Market
How volatile is Glanbia's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
How Many Glanbia plc (ISE:GL9) Shares Do Institutions Own?2 weeks ago | Simply Wall St
Who Has Been Buying Glanbia plc (ISE:GL9) Shares?4 weeks ago | Simply Wall St
Does Glanbia's (ISE:GL9) Statutory Profit Adequately Reflect Its Underlying Profit?Valuation
Is Glanbia undervalued compared to its fair value and its price relative to the market?
37.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GL9 (€9.86) is trading below our estimate of fair value (€15.79)
Significantly Below Fair Value: GL9 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GL9 is good value based on its PE Ratio (16.1x) compared to the Food industry average (16.8x).
PE vs Market: GL9 is poor value based on its PE Ratio (16.1x) compared to the Irish market (14.2x).
Price to Earnings Growth Ratio
PEG Ratio: GL9 is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: GL9 is overvalued based on its PB Ratio (1.7x) compared to the XE Food industry average (1.1x).
Next Steps
Future Growth
How is Glanbia forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
8.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GL9's forecast earnings growth (8.9% per year) is above the savings rate (0.7%).
Earnings vs Market: GL9's earnings (8.9% per year) are forecast to grow slower than the Irish market (14.8% per year).
High Growth Earnings: GL9's earnings are forecast to grow, but not significantly.
Revenue vs Market: GL9's revenue (3.2% per year) is forecast to grow slower than the Irish market (6% per year).
High Growth Revenue: GL9's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GL9's Return on Equity is forecast to be low in 3 years time (12.5%).
Next Steps
Past Performance
How has Glanbia performed over the past 5 years?
6.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GL9 has high quality earnings.
Growing Profit Margin: GL9's current net profit margins (4.6%) are lower than last year (7.5%).
Past Earnings Growth Analysis
Earnings Trend: GL9's earnings have grown by 6.7% per year over the past 5 years.
Accelerating Growth: GL9's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GL9 had negative earnings growth (-22.8%) over the past year, making it difficult to compare to the Food industry average (1.1%).
Return on Equity
High ROE: GL9's Return on Equity (10.6%) is considered low.
Next Steps
Financial Health
How is Glanbia's financial position?
Financial Position Analysis
Short Term Liabilities: GL9's short term assets (€1.2B) exceed its short term liabilities (€955.3M).
Long Term Liabilities: GL9's short term assets (€1.2B) exceed its long term liabilities (€743.7M).
Debt to Equity History and Analysis
Debt Level: GL9's debt to equity ratio (52%) is considered high.
Reducing Debt: GL9's debt to equity ratio has reduced from 76.7% to 52% over the past 5 years.
Debt Coverage: GL9's debt is well covered by operating cash flow (24%).
Interest Coverage: GL9's interest payments on its debt are well covered by EBIT (8.6x coverage).
Balance Sheet
Next Steps
Dividend
What is Glanbia's current dividend yield, its reliability and sustainability?
2.70%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GL9's dividend (2.7%) is higher than the bottom 25% of dividend payers in the Irish market (2.51%).
High Dividend: GL9's dividend (2.7%) is low compared to the top 25% of dividend payers in the Irish market (5.25%).
Stability and Growth of Payments
Stable Dividend: GL9's dividends per share have been stable in the past 10 years.
Growing Dividend: GL9's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (43.6%), GL9's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GL9's dividends in 3 years are forecast to be well covered by earnings (32.9% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.4yrs
Average management tenure
CEO
Siobhán Talbot (55yo)
6.58yrs
Tenure
€1,394,000
Compensation
Ms. Siobhán Talbot, B.Comm., FCA has been the Group Managing Director of Glanbia plc since November 12, 2013 and its Executive Director since July 1, 2009. Ms. Talbot served as Group Finance Director at Gl ...
CEO Compensation Analysis
Compensation vs Market: Siobhán's total compensation ($USD1.55M) is about average for companies of similar size in the Irish market ($USD1.76M).
Compensation vs Earnings: Siobhán's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Group MD & Executive Director | 6.58yrs | €1.39m | 0.10% €3.0m | |
| Group Finance Director & Executive Director | 6.58yrs | €1.02m | 0.038% €1.1m | |
| Chief Executive Officer of Glanbia Nutritionals | 1.42yrs | €289.00k | 0.053% €1.5m | |
| Chief Executive Officer of Glanbia Performance Nutrition | 1.42yrs | €222.00k | 0.035% €1.0m | |
| Group Director of Strategic Planning & Investor Relations | no data | no data | no data | |
| Head of Corporate Communications | no data | no data | no data | |
| Group Corporate Development Director | 5.25yrs | no data | no data | |
| Director of Group Human Resources & Corporate Affairs | 5.5yrs | no data | no data | |
| Group Secretary | 15yrs | no data | 0.014% €413.7k | |
| Chief Executive of Glanbia Ingredients Ireland Limited | 2.92yrs | no data | no data |
5.4yrs
Average Tenure
54.5yo
Average Age
Experienced Management: GL9's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Group MD & Executive Director | 6.58yrs | €1.39m | 0.10% €3.0m | |
| Group Finance Director & Executive Director | 6.58yrs | €1.02m | 0.038% €1.1m | |
| Senior Independent Director | 1.08yrs | €95.00k | 0.0026% €75.6k | |
| Member of the US Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 7.25yrs | €95.00k | 0.0034% €98.6k | |
| Chairman | 2yrs | €113.00k | 0.011% €332.5k | |
| Member of The US Advisory Board | no data | no data | no data | |
| Vice Chairman | 3yrs | €60.00k | 0.0025% €71.9k | |
| Non-Executive Director | 3yrs | €43.00k | 0.012% €343.3k | |
| Vice Chairman | 2yrs | €60.00k | 0.0039% €113.5k |
3.0yrs
Average Tenure
60yo
Average Age
Experienced Board: GL9's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GL9 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Glanbia plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Glanbia plc
- Ticker: GL9
- Exchange: ISE
- Founded: 1964
- Industry: Packaged Foods and Meats
- Sector: Food, Beverage & Tobacco
- Market Cap: €2.909b
- Shares outstanding: 295.23m
- Website: https://www.glanbia.com
Number of Employees
Location
- Glanbia plc
- Glanbia House
- Ring Road
- Kilkenny
- Co. Kilkenny
- R95 E866
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GLB | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| GL9 | ISE (Irish Stock Exchange) | Yes | Ordinary Shares | IE | EUR | Jan 1992 |
| GLAP.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jan 1992 |
| GL9I | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| GL9 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| GLBL | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| GLB N | BMV (Bolsa Mexicana de Valores) | Yes | Ordinary Shares | MX | MXN | Jan 1992 |
| GLAP.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Oct 1998 |
Biography
Glanbia plc operates as a nutrition company. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland. The Glanbia Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, e-Commerce, and gyms, as well the food, drug, mass, and club channels. The Glanbia Nutritionals segment engages in the manufacture and sale of cheese, dairy and non-dairy nutritional and functional ingredients, and vitamin and mineral premixes. The Glanbia Ireland segment produces and sells a range of value added dairy ingredients and consumer products. This segment also sells animal nutrition and fertilizer products; and operates a chain of agricultural retail outlets in Ireland. The company also engages in the financing, research and development, property and land dealing, receivables management, management, property leasing, business service, and weight management solutions businesses. It provides its products under the Optimum Nutrition, SlimFast, BSN, Isopure, Nutramino, ABB, think!, Amazing Grass, and Body & Fit brands. The company has operations in North America, Europe, and internationally. Glanbia plc was founded in 1964 and is headquartered in Kilkenny, Ireland.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/01 21:40 |
| End of Day Share Price | 2020/06/01 00:00 |
| Earnings | 2020/01/04 |
| Annual Earnings | 2020/01/04 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.